Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / ADS
-
Number of holders
-
34
-
Total 13F shares, excl. options
-
20.5M
-
Shares change
-
+818K
-
Total reported value, excl. options
-
$344M
-
Value change
-
+$16.8M
-
Number of buys
-
15
-
Number of sells
-
-8
-
Price
-
$17.37
Significant Holders of Silence Therapeutics plc - ADS (SLN) as of Q4 2023
36 filings reported holding SLN - Silence Therapeutics plc - ADS as of Q4 2023.
Silence Therapeutics plc - ADS (SLN) has 34 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 20.5M shares
.
Largest 10 shareholders include Lombard Odier Asset Management (USA) Corp (3.88M shares), Lombard Odier Asset Management (Europe) Ltd (3.61M shares), Artal Group S.A. (3M shares), TCG Crossover Management, LLC (2.1M shares), Deep Track Capital, LP (1.95M shares), BVF INC/IL (1.51M shares), Aquilo Capital Management, LLC (1.04M shares), Frazier Life Sciences Management, L.P. (881K shares), Vivo Capital, LLC (510K shares), and Logos Global Management LP (400K shares).
This table shows the top 34 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.